[go: up one dir, main page]

HUP9903373A2 - Mikofenolátot tartalmazó,bélben oldodó bevonattal ellátott gyógyszerkészítmények - Google Patents

Mikofenolátot tartalmazó,bélben oldodó bevonattal ellátott gyógyszerkészítmények

Info

Publication number
HUP9903373A2
HUP9903373A2 HU9903373A HUP9903373A HUP9903373A2 HU P9903373 A2 HUP9903373 A2 HU P9903373A2 HU 9903373 A HU9903373 A HU 9903373A HU P9903373 A HUP9903373 A HU P9903373A HU P9903373 A2 HUP9903373 A2 HU P9903373A2
Authority
HU
Hungary
Prior art keywords
mycophenolate
enteric
pharmaceutical compositions
coated pharmaceutical
diseases
Prior art date
Application number
HU9903373A
Other languages
English (en)
Inventor
Barbara Haeberlin
Ching Pong Mak
Armin Meinzer
Jacky Vonderscher
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9903373(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9607564.3A external-priority patent/GB9607564D0/en
Priority claimed from GBGB9622028.0A external-priority patent/GB9622028D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP9903373A2 publication Critical patent/HUP9903373A2/hu
Publication of HUP9903373A3 publication Critical patent/HUP9903373A3/hu
Publication of HU224919B1 publication Critical patent/HU224919B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgyát mikofenolátot tartalmazó készítmény, ennekalkalmazása képezi, azzal jellemezve, hogy a mikofenolátsók bélbenoldódó bevonattal vannak ellátva. Ezzel biztosítható, hogy a hatóanyaga bélrendszer felső részében szabaduljon fel. A készítmények,különösen immunszuppresszív indikációk esetében, főként a szerv,szövet vagy sejt allograft vagy xenograft (például átültetés utáni)kilökődése vagy immunrendszeri eredetű betegségek(autoimmunbetegségek) ellen hatásosak. Ó
HU9903373A 1996-04-12 1997-04-10 Enteric-coated pharmaceutical compositions of mycophenolate HU224919B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9607564.3A GB9607564D0 (en) 1996-04-12 1996-04-12 Organic compounds
GBGB9622028.0A GB9622028D0 (en) 1996-10-24 1996-10-24 Organic compounds
PCT/EP1997/001800 WO1997038689A2 (en) 1996-04-12 1997-04-10 Enteric-coated pharmaceutical compositions of mycophenolate

Publications (3)

Publication Number Publication Date
HUP9903373A2 true HUP9903373A2 (hu) 2001-04-28
HUP9903373A3 HUP9903373A3 (en) 2001-05-28
HU224919B1 HU224919B1 (en) 2006-04-28

Family

ID=26309105

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903373A HU224919B1 (en) 1996-04-12 1997-04-10 Enteric-coated pharmaceutical compositions of mycophenolate

Country Status (34)

Country Link
US (3) US6025391A (hu)
EP (2) EP1221316A1 (hu)
JP (2) JP3779732B2 (hu)
CN (1) CN1104238C (hu)
AR (2) AR006583A1 (hu)
AT (2) AT408415B (hu)
AU (1) AU725388B2 (hu)
BE (1) BE1010963A3 (hu)
BR (1) BR9708624A (hu)
CO (1) CO4900024A1 (hu)
CY (1) CY2243B1 (hu)
CZ (1) CZ291811B6 (hu)
DE (4) DE122004000038I2 (hu)
DK (1) DK0892640T3 (hu)
ES (2) ES2216141T3 (hu)
FR (1) FR2747920B1 (hu)
GB (1) GB2326339B (hu)
GR (1) GR1002893B (hu)
HK (1) HK1051484A1 (hu)
HU (1) HU224919B1 (hu)
ID (1) ID18663A (hu)
IE (1) IE970267A1 (hu)
IL (1) IL126431A (hu)
IT (1) IT1297045B1 (hu)
LU (1) LU91094I2 (hu)
MY (1) MY119049A (hu)
NL (1) NL300157I2 (hu)
NO (2) NO322891B1 (hu)
NZ (1) NZ332117A (hu)
PT (1) PT892640E (hu)
RU (2) RU2203659C2 (hu)
TR (1) TR199802056T2 (hu)
TW (1) TW457098B (hu)
WO (1) WO1997038689A2 (hu)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US20030050692A1 (en) * 2000-12-22 2003-03-13 Avantec Vascular Corporation Delivery of therapeutic capable agents
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
RU2277090C9 (ru) * 2002-08-29 2006-09-10 Байокон Лимитид Способ получения натриевой соли микофеноловой кислоты, являющейся иммунодепрессантным средством
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0314553D0 (en) * 2003-06-21 2003-07-30 Weatherford Lamb Electric submersible pumps
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
PT1729797E (pt) * 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
MXPA06005660A (es) 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Impureza de micofenolato mofetil.
WO2006012385A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1917010A2 (en) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
EP1913138B1 (en) * 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
CN1985994B (zh) * 2005-12-19 2011-01-12 康泰乐(北京)医药科技发展有限公司 改进的包含霉酚酸盐的包有肠溶衣的药物组合物
JP2009526771A (ja) * 2006-02-13 2009-07-23 ノバルティス アクチエンゲゼルシャフト 高投与量のミコフェノール酸（ｍｐａ）
JP2007230948A (ja) * 2006-03-02 2007-09-13 Univ Meijo 腸溶性化硬カプセル
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20080182998A1 (en) * 2007-01-25 2008-07-31 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
WO2008127663A1 (en) * 2007-04-11 2008-10-23 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Method for reducing impurity level in mycophenolic acid fermentation
WO2009022355A1 (en) * 2007-08-13 2009-02-19 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
WO2013041205A1 (de) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Neue therapeutische konzepte zur behandlung von gefässerkrankungen
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
KR102351422B1 (ko) 2014-01-06 2022-01-13 실드 티엑스 (유케이) 리미티드 철 트리말톨의 복용량 양생법
ES2753361T3 (es) 2014-02-24 2020-04-08 Alkermes Pharma Ireland Ltd Sulfonamida y profármacos de fumaratos de sulfinamida y su uso en el tratamiento de diversas enfermedades
GB201418710D0 (en) 2014-10-21 2014-12-03 Iron Therapeutics Holdings Ag Dosage regimen
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
CN117177749A (zh) 2021-03-03 2023-12-05 萨那生物科技公司 与心肌细胞疗法一起使用的免疫抑制疗法以及相关的方法和组合物
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1158387A (en) * 1967-06-13 1969-07-16 Ici Ltd Procedure for Isolation of Mycophenolic Acid
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
JPS5542995B2 (hu) * 1972-02-24 1980-11-04
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US4005108A (en) * 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4234684A (en) * 1979-12-11 1980-11-18 Eli Lilly And Company Method of preparing mycophenolic acid glucoside
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4727069A (en) * 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4847381A (en) * 1987-08-31 1989-07-11 American Cyanamid Company 2-Phenyl-4-quinoline carboxylic acids
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5372298A (en) * 1992-01-07 1994-12-13 The Regents Of The University Of California Transient liquid phase ceramic bonding
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
EP0721335B1 (en) * 1993-10-01 2005-08-31 Roche Palo Alto LLC Mycophenolate mofetil high dose oral suspensions
WO1995013082A1 (en) * 1993-11-08 1995-05-18 Pharmagenesis, Inc. Immunotherapy composition and method
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
EP0892640B1 (en) 2004-02-11
US6025391A (en) 2000-02-15
ES2178510B1 (es) 2004-08-16
IT1297045B1 (it) 1999-08-03
FR2747920B1 (fr) 1999-12-31
DE19781690D2 (de) 1999-04-08
WO1997038689A3 (en) 1997-12-04
IL126431A0 (en) 1999-08-17
EP0892640A2 (en) 1999-01-27
NO2007004I2 (no) 2009-10-19
MY119049A (en) 2005-03-31
CN1104238C (zh) 2003-04-02
HU224919B1 (en) 2006-04-28
TW457098B (en) 2001-10-01
FR2747920A1 (fr) 1997-10-31
PT892640E (pt) 2004-06-30
GB2326339B (en) 2000-04-19
HK1016490A1 (en) 1999-11-05
CN1215991A (zh) 1999-05-05
ID18663A (id) 1998-04-30
NZ332117A (en) 2000-04-28
JP2006063086A (ja) 2006-03-09
GB9821304D0 (en) 1998-11-25
NO984728L (no) 1998-12-02
AR006583A1 (es) 1999-09-08
AU725388B2 (en) 2000-10-12
NO2007004I1 (no) 2007-04-16
CZ291811B6 (cs) 2003-06-18
IE970267A1 (en) 1997-10-22
CY2243B1 (en) 2003-07-04
ITRM970207A1 (it) 1998-10-11
AU2384397A (en) 1997-11-07
US6172107B1 (en) 2001-01-09
NL300157I1 (nl) 2004-10-01
DK0892640T3 (da) 2004-05-10
NL300157I2 (nl) 2004-12-01
GR1002893B (el) 1998-04-10
DE122004000038I1 (de) 2006-01-26
DE69727559T2 (de) 2004-12-16
JP2000503665A (ja) 2000-03-28
US6306900B1 (en) 2001-10-23
CO4900024A1 (es) 2000-03-27
ES2216141T3 (es) 2004-10-16
LU91094I2 (fr) 2004-10-11
CZ326798A3 (cs) 1999-01-13
BE1010963A3 (fr) 1999-03-02
ATA905997A (de) 2001-04-15
ES2178510A1 (es) 2002-12-16
AR059693A2 (es) 2008-04-23
NO984728D0 (no) 1998-10-09
TR199802056T2 (xx) 1999-02-22
JP3779732B2 (ja) 2006-05-31
HUP9903373A3 (en) 2001-05-28
RU2615397C2 (ru) 2017-04-04
WO1997038689A2 (en) 1997-10-23
IL126431A (en) 2005-03-20
NO322891B1 (no) 2006-12-18
AT408415B (de) 2001-11-26
RU2203659C2 (ru) 2003-05-10
HK1051484A1 (en) 2003-08-08
GB2326339A (en) 1998-12-23
BR9708624A (pt) 1999-08-03
DE122004000038I2 (de) 2006-04-27
DE69727559D1 (de) 2004-03-18
ATE259228T1 (de) 2004-02-15
EP1221316A1 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
HUP9903373A2 (hu) Mikofenolátot tartalmazó,bélben oldodó bevonattal ellátott gyógyszerkészítmények
RU98120360A (ru) Фармацевтические композиции на основе микофенолята с энтеросолюбильным покрытием
DK1131065T3 (da) Diakyldumarater til behandling af autoimmunsygdomme
CA2310888A1 (en) Monoclonal human natural antibodies
NO985145D0 (no) Farmas°ytiske preparater for forsinket frigj°ring av uoppl°selige, aktive bestanddeler
NO158417C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive urinstoffer og tiourinstoffer.
Rangiwai Maori Prophetic Movements as Sites of Political Resistance: A Critical Analysis
NO923887L (no) Hybrid kalsitonin
DK0745071T3 (da) 4-Amino-6-substitueret mycophenolsyre og derivater med immunsuppressiv virkning
Williams Adaptation and acclimatisation in humans and animals at high altitude
Morris et al. Design is not Enough!
Dulles Yves Congar: In appreciation.
Allen Toward a “more perfect union”: A commingling of constitutional ideals and Christian precepts
Salzmann Stability or Chaos? Power Elites in Lusignan Cyprus between the 1360s and 1390s
Edwards The Two Witnesses of Revelation 11
Patterson Henry IV and the Huguenot Appeal for a Return to Poissy
Angel et al. Scanning electron microscope study of the feather follicle wall attachment in chickens
Farley et al. Winners & losers.
DEUTSCHER Wolfgang Cagnolati, the President of the VDC with Judith Morris who represented the British Contact Lens Association at the 35th Annual Clinical Meeting in Berlin.
Beatty Systemic Aesthetics: Kiowa-Apache Ritual
York The 1993 parliament of the world's religions: The Palmer House Hilton, Chicago, Illinois, 28 August‐5 September, 1993
Price God's Channel of Truth--: Is it the Watchtower?
Pixley et al. THE THREEFOLD PURPOSE OF MILLENNIAL TEMPLE SACRIFICES
Sohn The divine election of Israel
Bueno et al. Intestinal retransplantation

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: MYCOPHENOLIC ACID; REG. NO/DATE: OGYI-T-10074/01 20050302; FIRST REG.: CH 5611501, 5611502 20021024

Spc suppl protection certif: S0600002

Filing date: 20060628

Expiry date: 20170410

QB4A Exploitation contract

Name of requester: NOVARTIS HUNGARIA KFT., HU